New AI tool for prostate MRI analysis to support PI-RADS scoring

Innovative technology performs automatic segmentation and lesion detection in prostate MRIs to aid in PI-RADS scoring for prostate cancer management

TEL AVIV, Israel and SAN JOSE, Calif.–(BUSINESS WIRE)– RSIP Vision, an experienced leader in innovating medical imaging through advanced artificial intelligence (AI) and computer vision solutions, today announces a new tool for prostate MRI analysis. The tool performs segmentation of the prostate, its subsections and lesions. It analyzes the intensity, restriction, size and shape of the lesions and provides a baseline for the PI-RADS (Prostate Imaging–Reporting and Data System) score. This information is transmitted to the radiologist for review, reducing review time and the rate of misdiagnosis. This new vendor-neutral technology will be available to third-party MRI manufacturers and visualization solutions, enabling a more accurate and efficient way to report prostate MRI examination.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220411005238/en/

“MRI is an advanced imaging tool, specifically for soft tissues like the prostate, with potential for improvement through AI,” said Ron Soferman, CEO of RSIP Vision. “Deep learning (DL) algorithms can be developed for precise segmentation of prostate, transition zone (TZ), peripheral zone (PZ) and suspicious lesions. The system can automatically detect and calculate lesion dimensions, volume, intensity, restriction and edge softness in all different scan settings. Additionally, this tool can compare current and previous scans and highlight differences, providing additional information to the radiologist prior to scoring. »

The PI-RADS scoring method was developed to provide a uniform scale for the assessment of prostate cancer. It consists of descriptive parameters for the shape, location, intensity and restriction of the lesion, each corresponding to a different score representing suspicious features of prostate cancer. Currently, it is performed manually and is a time-consuming task for radiologists, with a high rate of inter-observer variability. RSIP Vision’s new PI-RADS Assistant provides objective prostate MRI analysis, with measurable statistics that can be used to improve scoring accuracy. Also, it is common to perform follow-up scans in patients diagnosed with prostate cancer. The PI-RADS Assistant compares lesions from previous scans and presents the differences to the radiologist, providing a map of lesion growth, wilting or stability.

“Prostate MRIs are very common and their frequency is increasing with increasing life expectancy,” said Dr. Rabeeh Fares, senior radiologist at Sourasky Medical Center, Tel Aviv, Israel. “Examining these scans is a big part of the radiologist’s workload. The PI-RADS Assistant will dramatically reduce exam time, improve scoring accuracy and precision, and ultimately lead to better clinical outcomes.

About RSIP Vision

RSIP Vision is at the forefront of innovation in visual intelligence for medical devices, through advanced AI and computer vision applications. A recognized global leader, with a long track record and over 25 years in the field, trusted by the largest industry-leading medical device companies. RSIP Vision offers clinical-grade AI solutions that provide medical device companies with advanced visual intelligence capabilities, to stay ahead of the rapid AI adoption curve and maintain their competitive advantage. Our software can be found in medical devices at leading facilities around the world, ensuring our customers stay on top of the latest advances in medical computer vision.

RSIP Vision is headquartered in Jerusalem and has a US office in San Jose, California.

More information is available on the company’s website: www.rsipvision.com

Comments are closed.